<DOC>
	<DOCNO>NCT02605772</DOCNO>
	<brief_summary>To investigate Safety Efficacy Acarbose+Saxagliptin Compared With Metformin+Saxagliptin Patients With Type 2 Diabetes,100 patient T2DM enrol study.They randomly assign Acarbose+Saxagliptin Metformin+Saxagliptin group.HbA1c，fasting postprandial C-peptide observe intervention .</brief_summary>
	<brief_title>Safety Efficacy Acarbose+Saxagliptin Compared With Metformin+Saxagliptin Patients With Type 2 Diabetes</brief_title>
	<detailed_description>Participants come study assign two groups：Acarbose+Saxagliptin Metformin+Saxagliptin . It may take 1 week stabilize standardize dose , investigator follow-up patient 3 months.During period , patient ask come back investigator center receive related examination every month . The investigator detect HbA1c，fasting postprandial C-peptide intervention .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Acarbose</mesh_term>
	<criteria>Newly diagnose type 2 diabetes mellitus（course disease le one year） receive drug treatment . T2DM patient receive drug treatment three month least . HbA1c 7.510 % . New worsen sign symptom coronary heart disease Medical history active liver disease kidney disease Poorly control hypertension（systolic blood pressure &gt; 160mmHg diastolic blood pressure &gt; 95mmHg） A clinically important hematological disorder A history intolerance hypersensitivity contraindication study medication ( include saxagliptin , metformin , acarbose ) Is pregnant breast feeding expect conceive donate egg A medical history drug abuse Can follow time Endocrinological diseases（eg： hyperthyroidism、hypothyroidisn cushing syndrom） Gastrointestinal disease Mental disorser Hypoxic disease</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>